High-throughput method developed for single-cell metabolic profiling
Scientists have presented a new method for generating the metabolic profiles of cells which could answer questions on conditions such as cancer and liver disease.
List view / Grid view
Scientists have presented a new method for generating the metabolic profiles of cells which could answer questions on conditions such as cancer and liver disease.
Researchers in Japan propose that the antimalarial drug mefloquine could be repurposed to effectively treat SARS-CoV-2.
Dr Robert Hewitt explains why the need of biospecimen brokers to protect their commercially-sensitive information can result in significant issues for industry end-users and the results of their research.
In brain tissues, researchers have shown that two different nanosized polyoxoniobate molecules can inhibit the assembly of amyloid plaques.
With over 20 years’ of expertise in phage display, IRBM applies its extensive peptide and antibody libraries to discover lead therapeutic candidates. Dr Licia Tomei, Director of Display Technologies, IRBM, discusses the company’s phage display capabilities and how they accelerate the drug discovery process.
Researchers have found that the CDK inhibitor AT7519 could be used to treat pancreatic cancer patients whose tumours are addicted to mutant KRAS.
Researchers have shown that the leakage of mitochondrial double-stranded DNA into the cell can contribute to Parkinson's disease.
Researchers have shown that omega-3 very long-chain polyunsaturated fatty acids can block SARS-CoV-2 and protect lung cells.
Researchers have successfully created an unbiased, high-throughput microtitration assay for the quantification of Ebola virus in cell lines.
A synthetic antiviral named R327 has shown promise in initial tests against SARS-CoV-2 and is now advancing to the next stage of in vitro studies.
Having identified the histone demethylase KDM5A as a multiple myeloma target, researchers developed a KDM5 inhibitor to treat the cancer.
Researchers have developed a set of compounds designed to stop the malaria parasite being able to burst out of red blood cells and replicate.
An airway-on-a-chip has been used to show that amodiaquine inhibits SARS-CoV-2 infection, making it a potential COVID-19 therapeutic.
Scientists have developed a 3D lung-on-a-chip model of the distal lung and alveolar structures, enabling the study of COVID-19.
Scientists have shown that the SARS-CoV-2 Spike protein can initiate gene expression changes, potentially explaining long COVID symptoms.